前列腺癌新靶点CDK19的PET显像研究
研究基于癌症基因组图谱(TCGA)数据库及活检证实的高危转移性前列腺癌队列,确认CDK19在高级别转移性前列腺癌中过表达且与转移状态和肿瘤分期相关,并与PSMA和PSA水平独立。作者合成靶向CDK19的镓-68(68Ga)标记小分子68Ga-IRM-015-DOTA,在体外细胞、小鼠异种移植模型和PDX模型中评估其特异性摄取;结果显示神经内分泌前列腺癌(NEPC)和去势抵抗性前列腺癌(CRPC)异种移植瘤均有类似信号,而68Ga-PSMA-11仅染色CRPC异种移植瘤。
要点
- CDK19在活检证实的高危转移性前列腺癌中过表达,其表达与转移状态和肿瘤分期相关。
- 68Ga-IRM-015-DOTA对前列腺癌细胞具有特异性,其他癌细胞摄取少量。
- NEPC和CRPC异种移植瘤对68Ga-IRM-015-DOTA信号强度相似,68Ga-PSMA-11仅染色CRPC异种移植瘤。
核心结论
- 作者认为68Ga-CDK19 PET/CT在体外、体内和PDX模型中可检测有或无PSMA表达的病灶。
- 作者认为68Ga-CDK19可能值得在前瞻性队列中作为PET扫描的预测性生物标志物进一步评估,并可能有助于识别独立于PSMA的前列腺癌分子类型。
研究设计与样本
- 研究利用癌症基因组图谱(TCGA)数据库及作者队列中活检证实的高危转移性前列腺癌男性样本,识别CDK19与PSMA表达。
- 体外使用PDX来源的neP-09和P-16原代细胞进行细胞摄取和成像质谱流式分析。
- 体内使用异种移植小鼠模型和阻断实验评估镓-68(Ga-68)标记的68Ga-IRM-015-DOTA对CDK19的特异性摄取,并通过PET/CT成像数据估算器官吸收剂量。
主要发现
- 研究组曾报道新型组织特异性基因CDK19在高危转移性前列腺癌中过表达,且CDK19表达与转移状态和肿瘤分期相关,并与PSMA和PSA水平独立。
- 68Ga-IRM-015-DOTA对前列腺癌细胞具有特异性,但其他癌细胞也少量摄取68Ga-IRM-015-DOTA。
- 小鼠成像数据显示NEPC和CRPC异种移植瘤对68Ga-IRM-015-DOTA呈现相似信号强度,而68Ga-PSMA-11仅染色CRPC异种移植瘤。
- 在携带CDK19的肿瘤异种移植瘤上进行的阻断实验阐明了靶点特异性。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 作者在结论中指出68Ga-CDK19可能值得在前瞻性队列中进一步评估,原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate-specific membrane antigen (PSMA)-positron emission tomography (PET) is a superior method to predict patients' risk of cancer progression and response to specific therapies. However, its performance is limited for neuroendocrine prostate cancer (NEPC) and PSMA-low prostate cancer cells, resulting in diagnostic blind spots. Hence, identifying novel specific targets is our aim for diagnosing those prostate cancers with low PSMA expression. METHODS: The Cancer Genome Atlas (TCGA) database and our cohorts from men with biopsy-proven high-risk metastatic prostate cancer were used to identify CDK19 and PSMA expression. PDX lines neP-09 and P-16 primary cells were used for cellular uptake and imaging mass cytometry in vitro. To evaluate in vivo CDK19-specific uptake of gallium(Ga)-68-IRM-015-DOTA, xenograft mice models and blocking assays were used. PET/CT imaging data were obtained to estimate the absorbed dose in organs. RESULTS: Our study group had reported the overexpression of a novel tissue-specific gene CDK19 in high-risk metastatic prostate cancer and CDK19 expression correlated with metastatic status and tumor staging, independently with PSMA and PSA levels. Following up on this new candidate for use in diagnostics, small molecules targeting CDK19 labeled with Ga-68 (68Ga-IRM-015-DOTA) were used for PET in this study. We found that the 68Ga-IRM-015-DOTA was specificity for prostate cancer cells, but the other cancer cells also took up little 68Ga-IRM-015-DOTA. Importantly, mouse imaging data showed that the NEPC and CRPC xenografts exhibited similar signal strength with 68Ga-IRM-015-DOTA, but 68Ga-PSMA-11 only stained the CRPC xenografts. Furthermore, target specificity was elucidated by a blocking experiment on a CDK19-bearing tumor xenograft. These data concluded that 68Ga-CDK19 PET/CT was an effective technology to detect lesions with or without PSMA in vitro, in vivo, and in the PDX model. CONCLUSION: Thus, we have generated a novel PET small molecule with predictive value for prostate cancer. The findings indicate that 68Ga-CDK19 may merit further evaluation as a predictive biomarker for PET scans in prospective cohorts and may facilitate the identification of molecular types of prostate cancer independent of PSMA.
引用
- Dai D, Yu J, Huang T, et al. PET imaging of new target CDK19 in prostate cancer. Eur J Nucl Med Mol Imaging. 2023. PMID: 37278941. doi:10.1007/s00259-023-06277-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。